Adults without pretreatment and adults with pretreatment for whom an integrase inhibitor is mandatory have fewer side effects under dolutegravir than under the comparator therapy. No added benefit could be determined for pretreated adults who do not require INIs (i. e. in whom no integrase inhibitor is indicated) and for adolescents above 12 years of age, because there were no study data.

Source: Dolutegravir in HIV-1 infection: Added benefit in adult patients